Assessment of proliferation indicators in residual prostatic adenocarcinoma cells after radical external beam radiotherapy

✍ Scribed by Ljung, G.; Egevad, L.; Norberg, M.; de la Torre, M.; Holmberg, L.; Busch, C.; Nilsson, S.

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 724 KB
• Volume: 29
• Category: Article
• ISSN: 0270-4137
• DOI: 10.1002/(sici)1097-0045(199611)29:5<303::aid-pros5>3.0.co;2-a

✦ Synopsis

BACKGROUND.

Fifty-five patients who had received radical external beam radiotherapy (RRT) for clinically staged, localized prostatic adenocarcinoma were examined with systematic sextant mapping with the help of transrectal ultrasound-guided core biopsies. The average follow-up after RRT was 6.8 years. Residual cancer was found histopathologically in 67% (37/55) of the patients investigated.

METHODS.

In the present report, the viability of these tumor cells was studied using immunohistochemical staining methods with the monoclonal antibodies MIBl and PC10, which are specific for the proliferation-associated antigens Ki-67 and F " A .

RESULTS.

Available data concerning proliferating activity in the pretreatment situation in 12 of these patients revealed that proliferating activity was substantially reduced in the majority of cases after RRT. Post-RRT, Ki-67, and PCNA activity was nonetheless found to varying degrees in 64% and 94% of the 36 evaluable tumor-harboring specimens, respectively. In the majority of cases, the proportion of proliferating cells, designated "score", was low. However, Ki-67 scores of up to 8% and PCNA scores of up to 50% were obtained in 35% (8/23) and 97% (33/34) of the specimens, respectively, with proliferative activity. There was no significant correlation between tumor grade and proliferative score in the follow-up biopsies. In the 36 cases investigated, endocrine treatment did not influence the proliferation results. CONCLUSIONS. The present study demonstrates a proliferative capacity in residual tumor cells in a long-term follow-up after RRT, suggesting that these cancer cells might have a biological sigruficance.